Biochemical markers identify influences on bone and cartilage degradation in osteoarthritis - the effect of sex, Kellgren-Lawrence (KL) score, Body Mass Index (BMI), oral salmon calcitonin (sCT) treatment and diurnal variation

[1]  M. Karsdal,et al.  The effect of oral salmon calcitonin delivered with 5-CNAC on bone and cartilage degradation in osteoarthritic patients: a 14-day randomized study. , 2010, Osteoarthritis and cartilage.

[2]  Kim Henriksen,et al.  Which elements are involved in reversible and irreversible cartilage degradation in osteoarthritis? , 2010, Rheumatology International.

[3]  M. Karsdal,et al.  Biochemical markers and the FDA Critical Path: How biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development , 2009, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[4]  M. Karsdal,et al.  Influence of food intake on the bioavailability and efficacy of oral calcitonin. , 2009, British Journal of Clinical Pharmacology.

[5]  M. Karsdal,et al.  Increased urinary excretion of C-telopeptides of type II collagen (CTX-II) predicts cartilage loss over 21 months by MRI. , 2009, Osteoarthritis and cartilage.

[6]  M. Karsdal,et al.  A Pharmacokinetic and Pharmacodynamic Comparison of Synthetic and Recombinant Oral Salmon Calcitonin , 2009, Journal of clinical pharmacology.

[7]  C. Christiansen,et al.  Investigation of the diurnal variation in bone resorption for optimal drug delivery and efficacy in osteoporosis with oral calcitonin , 2008, BMC clinical pharmacology.

[8]  C. Christiansen,et al.  Tibolone inhibits bone resorption without secondary positive effects on cartilage degradation , 2008, BMC musculoskeletal disorders.

[9]  K Henriksen,et al.  Should subchondral bone turnover be targeted when treating osteoarthritis? , 2008, Osteoarthritis and cartilage.

[10]  M. Karsdal,et al.  Biochemical Markers for Monitoring Response to Therapy: Evidence for Higher Bone Specificity by a Novel Marker Compared with Routine Markers , 2008, Cancer Epidemiology Biomarkers & Prevention.

[11]  M. Karsdal,et al.  Osteoclasts secrete non-bone derived signals that induce bone formation. , 2008, Biochemical and biophysical research communications.

[12]  M. Karsdal,et al.  Calcitonin Affects Both Bone and Cartilage , 2007 .

[13]  M. Karsdal,et al.  The effect of oral calcitonin on cartilage turnover and surface erosion in an ovariectomized rat model. , 2007, Arthritis and rheumatism.

[14]  S. Glasson,et al.  Osteoarthritis severity is sex dependent in a surgical mouse model. , 2007, Osteoarthritis and cartilage.

[15]  Chi-Hung Lin,et al.  Calcitonin induces podosome disassembly and detachment of osteoclasts by modulating Pyk2 and Src activities. , 2007, Bone.

[16]  K Knahr,et al.  Strategies for the prevention and management of osteoarthritis of the hip and knee. , 2007, Best practice & research. Clinical rheumatology.

[17]  M. Karsdal,et al.  Characterization of osteoclasts derived from CD14+ monocytes isolated from peripheral blood , 2006, Journal of Bone and Mineral Metabolism.

[18]  E. Thonar,et al.  Oral salmon calcitonin reduces Lequesne's algofunctional index scores and decreases urinary and serum levels of biomarkers of joint metabolism in knee osteoarthritis. , 2006, Arthritis and rheumatism.

[19]  R. Wallace,et al.  Effect of hormone therapy on risk of hip and knee joint replacement in the Women's Health Initiative. , 2006, Arthritis and rheumatism.

[20]  M. Young,et al.  Animal models of osteoarthritis: lessons learned while seeking the ‘Holy Grail’ , 2006, Current opinion in rheumatology.

[21]  D J Hunter,et al.  Classification of osteoarthritis biomarkers: a proposed approach. , 2006, Osteoarthritis and cartilage.

[22]  M. Karsdal,et al.  Relative contribution of matrix metalloprotease and cysteine protease activities to cytokine-stimulated articular cartilage degradation. , 2006, Osteoarthritis and cartilage.

[23]  M. Karsdal,et al.  Calcitonin is involved in cartilage homeostasis: is calcitonin a treatment for OA? , 2006, Osteoarthritis and cartilage.

[24]  L. Duong,et al.  Characterization of articular cartilage and subchondral bone changes in the rat anterior cruciate ligament transection and meniscectomized models of osteoarthritis. , 2006, Bone.

[25]  M. Karsdal,et al.  In vitro, ex vivo, and in vivo methodological approaches for studying therapeutic targets of osteoporosis and degenerative joint diseases: how biomarkers can assist? , 2005, Assay and drug development technologies.

[26]  C. Cooper,et al.  Urinary CTX-II and glucosyl-galactosyl-pyridinoline are associated with the presence and severity of radiographic knee osteoarthritis in men , 2005, Annals of the rheumatic diseases.

[27]  M. Karsdal,et al.  Oral salmon calcitonin induced suppression of urinary collagen type II degradation in postmenopausal women: a new potential treatment of osteoarthritis. , 2005, Bone.

[28]  S. Silverman,et al.  Rationale for the potential use of calcitonin in osteoarthritis. , 2005, Journal of musculoskeletal & neuronal interactions.

[29]  A. Galanos,et al.  Morphometric Changes in the Epiphyseal Plate of the Growing and Young Adult Male Rat After Long-Term Salmon Calcitonin Administration , 2005, Calcified Tissue International.

[30]  Claus Christiansen,et al.  Enlarged Waist Combined With Elevated Triglycerides Is a Strong Predictor of Accelerated Atherogenesis and Related Cardiovascular Mortality in Postmenopausal Women , 2005, Circulation.

[31]  E. Thonar,et al.  Treatment with calcitonin prevents the net loss of collagen, hyaluronan and proteoglycan aggregates from cartilage in the early stages of canine experimental osteoarthritis. , 2004, Osteoarthritis and cartilage.

[32]  D. Chappard,et al.  Effects of Calcitonin on Subchondral Trabecular Bone Changes and on Osteoarthritic Cartilage Lesions After Acute Anterior Cruciate Ligament Deficiency , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[33]  P. J. Larsen,et al.  Novel Associations Between Bioavailable Estradiol and Adipokines in Elderly Women With Different Phenotypes of Obesity: Implications for Atherogenesis , 2004, Circulation.

[34]  C. Christiansen,et al.  Safety and Efficacy of a Novel Salmon Calcitonin (sCT) Technology‐Based Oral Formulation in Healthy Postmenopausal Women: Acute and 3‐Month Effects on Biomarkers of Bone Turnover , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[35]  C. Christiansen,et al.  Suppression of elevated cartilage turnover in postmenopausal women and in ovariectomized rats by estrogen and a selective estrogen-receptor modulator (SERM) , 2004, Menopause.

[36]  A. Uitterlinden,et al.  A new marker for osteoarthritis: cross-sectional and longitudinal approach. , 2004, Arthritis and rheumatism.

[37]  M. C. Ovejero,et al.  The Chloride Channel Inhibitor NS3736 Prevents Bone Resorption in Ovariectomized Rats Without Changing Bone Formation , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[38]  C. Carlson,et al.  Effects of Estrogen Replacement Therapy on Bone Turnover in Subchondral Bone and Epiphyseal Metaphyseal Cancellous Bone of Ovariectomized Cynomolgus Monkeys , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[39]  L. Duong,et al.  The role of subchondral bone remodeling in osteoarthritis: reduction of cartilage degeneration and prevention of osteophyte formation by alendronate in the rat anterior cruciate ligament transection model. , 2004, Arthritis and rheumatism.

[40]  G. Lajoie,et al.  Inhibition of hydroxyapatite formation by osteopontin phosphopeptides. , 2004, The Biochemical journal.

[41]  L. Tankó,et al.  Ovariectomized rats as a model of postmenopausal osteoarthritis: validation and application , 2004, Arthritis research & therapy.

[42]  D. Felson,et al.  Osteoarthritis: is it a disease of cartilage or of bone? , 2004, Arthritis and rheumatism.

[43]  T. Spector,et al.  Evidence of altered bone turnover, vitamin D and calcium regulation with knee osteoarthritis in female twins. , 2003, Rheumatology.

[44]  P. Richette,et al.  Estrogens, cartilage, and osteoarthritis. , 2003, Joint, bone, spine : revue du rhumatisme.

[45]  C. Christiansen,et al.  Cartilage turnover assessed with a newly developed assay measuring collagen type II degradation products: influence of age, sex, menopause, hormone replacement therapy, and body mass index , 2003, Annals of the rheumatic diseases.

[46]  Claus Christiansen,et al.  Peripheral Adiposity Exhibits an Independent Dominant Antiatherogenic Effect in Elderly Women , 2003, Circulation.

[47]  T. Spector,et al.  The role of bone metabolism in osteoarthritis , 2003, Current rheumatology reports.

[48]  B. Lindgren,et al.  Effects of long-term estrogen replacement therapy on osteoarthritis severity in cynomolgus monkeys. , 2002, Arthritis and rheumatism.

[49]  C. Christiansen,et al.  Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTx): effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting. , 2002, Bone.

[50]  R. Zernicke,et al.  Periarticular cancellous bone changes following anterior cruciate ligament injury. , 2001, Journal of applied physiology.

[51]  R. Zernicke,et al.  Early regional adaptation of periarticular bone mineral density after anterior cruciate ligament injury. , 2000, Journal of applied physiology.

[52]  M. Hochberg,et al.  Joint Injury in Young Adults and Risk for Subsequent Knee and Hip Osteoarthritis , 2000, Annals of Internal Medicine.

[53]  E. Thonar,et al.  Synovial fluid levels of tumor necrosis factor alpha and oncostatin M correlate with levels of markers of the degradation of crosslinked collagen and cartilage aggrecan in rheumatoid arthritis but not in osteoarthritis. , 2000, Arthritis and rheumatism.

[54]  C. Christiansen,et al.  Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study. , 1999, The Journal of clinical endocrinology and metabolism.

[55]  E. Thonar,et al.  Treatment with calcitonin suppresses the responses of bone, cartilage, and synovium in the early stages of canine experimental osteoarthritis and significantly reduces the severity of the cartilage lesions. , 1999, Arthritis and rheumatism.

[56]  C. Hogstedt,et al.  Osteoarthrosis of the knee in men and women in association with overweight, smoking, and hormone therapy , 1999, Annals of the rheumatic diseases.

[57]  C. Christiansen,et al.  Serum CrossLaps One Step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen. , 1998, Clinical chemistry.

[58]  M. Hochberg,et al.  Erosive Osteoarthritis , 2010 .

[59]  T. Spector,et al.  Is hormone replacement therapy protective for hand and knee osteoarthritis in women?: The Chingford study , 1997, Annals of the rheumatic diseases.

[60]  E. Vignon,et al.  Calcitonin inhibits phospholipase A2 and collagenase activity of human osteoarthritic chondrocytes. , 1997, Osteoarthritis and cartilage.

[61]  N. Takahashi,et al.  Calcitonin-induced changes in the cytoskeleton are mediated by a signal pathway associated with protein kinase A in osteoclasts. , 1996, Endocrinology.

[62]  C. Christiansen,et al.  Tibolone: prevention of bone loss in late postmenopausal women. , 1996, The Journal of clinical endocrinology and metabolism.

[63]  D. Felson,et al.  The incidence and natural history of knee osteoarthritis in the elderly. The Framingham Osteoarthritis Study. , 1995, Arthritis and rheumatism.

[64]  A M Walker,et al.  Incidence of symptomatic hand, hip, and knee osteoarthritis among patients in a health maintenance organization. , 1995, Arthritis and rheumatism.

[65]  C. Christiansen,et al.  Marked diurnal variation in urinary excretion of pyridinium cross-links in premenopausal women. , 1992, The Journal of clinical endocrinology and metabolism.

[66]  T. Spector,et al.  Endogenous sex steroid levels in women with generalised osteoarthritis , 1991, Clinical Rheumatology.

[67]  Y. Henrotin,et al.  Effects of human and salmon calcitonin on human articular chondrocytes cultivated in clusters. , 1989, The Journal of clinical endocrinology and metabolism.

[68]  T. Chambers,et al.  The sensitivity of isolated osteoclasts to morphological transformation by calcitonin. , 1983, The Journal of clinical endocrinology and metabolism.

[69]  J. Fraser,et al.  Effect of calcitonin on glycosaminoglycan synthesis by embryo calf bone cells in vitro , 1969, Experientia.

[70]  T. Martin,et al.  STIMULATION OF GLYCOSAMINOGLYCAN SYNTHESIS BY THYROCALCITONIN PREPARATIONS , 1968, The Medical journal of Australia.

[71]  M. Karsdal,et al.  Calcitonin — A Drug of the Past or for the Future? , 2012, BioDrugs.

[72]  M. Karsdal,et al.  Investigations of inter- and intraindividual relationships between exposure to oral salmon calcitonin and a surrogate marker of pharmacodynamic efficacy , 2009, European Journal of Clinical Pharmacology.

[73]  M. Karsdal,et al.  Calcitonin affects both bone and cartilage: a dual action treatment for osteoarthritis? , 2007, Annals of the New York Academy of Sciences.

[74]  J. Houwing-Duistermaat,et al.  Clusters of biochemical markers are associated with radiographic subtypes of osteoarthritis (OA) in subject with familial OA at multiple sites. The GARP study. , 2007, Osteoarthritis and cartilage.

[75]  G. Herrero-Beaumont,et al.  Osteoporosis increases the severity of cartilage damage in an experimental model of osteoarthritis in rabbits. , 2007, Osteoarthritis and cartilage.

[76]  M. Karsdal,et al.  P88 EVALUATION OF JOINT PATHOLOGY BY MEASURING CARTILAGE DEGRADATION PRODUCTS IN JOINT EXTRACTS , 2006 .

[77]  J. Holst,et al.  Reduction of nocturnal rise in bone resorption by subcutaneous GLP-2. , 2004, Bone.

[78]  A. Kerin,et al.  Molecular basis of osteoarthritis: biomechanical aspects , 2002, Cellular and Molecular Life Sciences CMLS.

[79]  J. Cauley,et al.  Serum sex hormones and severity of osteoarthritis of the hand. , 1993, The Journal of rheumatology.

[80]  M. Hochberg,et al.  Osteoarthritis I: epidemiology. , 1984, Maryland state medical journal.

[81]  D. Felson,et al.  Sex hormones and the risk of osteoarthritis in women: epidemiological evidence. , 1996, Annals of the rheumatic diseases.

[82]  M. Karsdal,et al.  Optimizing bioavailability of oral administration of small peptides through pharmacokinetic and pharmacodynamic parameters: The effect of water and timing of meal intake on oral delivery of Salmon Calcitonin , 2008, BMC clinical pharmacology.